ADAR1 Partners, LP
10% Owner

ADAR1 Partners, LP insider trades: Keros Therapeutics (KROS) stock buys and sales

10% Owner, Keros Therapeutics Last trade Oct 15, 2025 5 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
7
Open-market trades
since 2024
2
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where ADAR1 Partners, LP reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Oct 15, 2025KROS↓ Sell$77.9M
Oct 15, 2025KROS↓ Sell$13.2M
Oct 15, 2025KROS↓ Sell$4.5M
Apr 9, 2025KROS↑ Buy$9.3M
Apr 9, 2025KROS↑ Buy$154K
Aug 12, 2024PIRS↑ Buy$80K
Aug 12, 2024PIRS↑ Buy$12K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other KROS insiders

Open-market trades in the last 12 months

About ADAR1 Partners, LP's insider trades

ADAR1 Partners, LP is a 10% owner of Keros Therapeutics (KROS). Since Aug 12, 2024, it has reported 4 open-market purchases worth $9.6M and 3 sales worth $95.7M on SEC Form 4. There have been no open-market trades in the last 12 months.

Its filings also include other transactions (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KROS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.